Parasite resistance to antimalarial drugs poses a serious threat to malaria control. The WorldWide Antimalarial Resistance Network (WWARN) aims to provide a collaborative platform to support the global malaria research effort. Here, we describe the “WWARN clinical trials publication library,” an open-access, up-to-date resource to streamline the synthesis of antimalarial safety and efficacy data.
The Democratic Republic of the Congo (DRC) harbors 11% of global malaria cases, yet little is known about the spatial and genetic structure of the parasite population in that country. We sequence 2537 Plasmodium falciparum infections, including a nationally representative population sample from DRC and samples from surrounding countries, using molecular inversion probes - a high-throughput genotyping tool. We identify an east-west divide in haplotypes known to confer resistance to chloroquine and sulfadoxine-pyrimethamine.
The identification of artemisinin (ART) in 1971 allowed treatment of malaria resistant to chloroquine, the prevailing drug at the time, and provided hope for a malaria-free world (1). Today, malaria control efforts have been very successful, with 32% fewer deaths over the past 8 years (2). However, the emergence of resistance to ART and other antimalarials threatens to become a major problem in the continuing program to eliminate and eventually eradicate malaria (3).
No abstract available
The available evidence demonstrates the need for more investment to improve both sampling and analytical methodology and to achieve consensus in defining different types of poor quality medicines.